MK-6194 for Vitiligo
Trial Summary
What is the purpose of this trial?
This trial is testing a new medication called MK-6194 to see if it can help people with non-segmental vitiligo. The goal is to determine if MK-6194 can reduce the white patches on their skin by helping repigment these areas. Researchers will compare the results over several months.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, it mentions that participants should not have received certain prohibited medications within specific timeframes before joining the study, so it's best to discuss your current medications with the study team.
Research Team
Medical Director
Principal Investigator
Merck Sharp & Dohme LLC
Eligibility Criteria
This trial is for individuals with non-segmental vitiligo, which causes loss of skin color in blotches. Participants must have had the condition for at least 6 months and show a certain amount of facial and body depigmentation. Those with hands and feet involvement or other forms of vitiligo are not eligible.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive subcutaneous MK-6194 or placebo for up to 24 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Extension
Participants may opt into continuation of treatment with MK-6194 regimen 1 or 2
Treatment Details
Interventions
- MK-6194
Find a Clinic Near You
Who Is Running the Clinical Trial?
Merck Sharp & Dohme LLC
Lead Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University